{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03059355",
      "OrgStudyIdInfo": {
        "OrgStudyId": "20170095"
      },
      "Organization": {
        "OrgFullName": "University of Miami",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.",
      "OfficialTitle": "A Phase I/II, Randomized, Placebo-controlled Comparative Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Bone Marrow (BM) Derived MSCs to Evaluate Cytokine Suppression in Patients With Chronic Inflammation Due to Metabolic Syndrome.",
      "Acronym": "CERES"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "April 12, 2018",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2025",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2026",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "February 6, 2017",
      "StudyFirstSubmitQCDate": "February 15, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 23, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 19, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 2, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Joshua M Hare",
        "ResponsiblePartyInvestigatorTitle": "Director of ISCI, Louis Lemberg Professor of Medicine",
        "ResponsiblePartyInvestigatorAffiliation": "University of Miami"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Joshua M Hare",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation. Cells administered via intravenous infusion (IV) and will be tested in 37 patients in two phases (Pilot and Randomized).",
      "DetailedDescription": "In this Study, cells administered via intravenous infusion (IV) will be tested in 37 patients in two phases (Pilot and Randomized):\n\nThe pilot phase will consist of 12 subjects and the randomized phase will consist of 25 subjects.\n\nSubjects in each pilot phase group (Group 1, 2, 3 and 4) will not be treated less than 5 days apart and will each undergo full evaluation post infusion to demonstrate there is no evidence of treatment emergent SAE's prior to proceeding with the treatment of further subjects.\n\nFor subjects randomized to Group 3, 4, C and D (BMMSCs); the cells will be derived from a sample of the subject's bone marrow (obtained by iliac crest aspiration) approximately 4-6 weeks prior to infusion.\n\nDuration of Study Participation will be 12 months (Follow-up will be at 2 weeks, 1 Month, 3, 6, and 12 months.)"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Endothelial Dysfunction",
          "Metabolic Syndrome",
          "Chronic Inflammation"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "19",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Pilot Phase: Group 1 (UCMSCs)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: UCMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Pilot Phase: Group 2 (UCMSCs - 100 million)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: UCMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Pilot Phase: Group 3 (BMMSCs - 20 million)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: BMMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Pilot Phase: Group 4 (BMMSCs -100 million)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: BMMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group A (UCMSCs - 20 Million)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: UCMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group B (UCMSCs - 100 million)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: UCMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group C (BMMSCs - 20 million)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: BMMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group D (BMMSCs - 100 million)",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: BMMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group E (Placebo)",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Five (5) subjects will be treated with a single administration of placebo delivered via peripheral intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "UCMSCs",
            "InterventionDescription": "Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group A (UCMSCs - 20 Million)",
                "Group B (UCMSCs - 100 million)",
                "Pilot Phase: Group 1 (UCMSCs)",
                "Pilot Phase: Group 2 (UCMSCs - 100 million)"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "BMMSCs",
            "InterventionDescription": "Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group C (BMMSCs - 20 million)",
                "Group D (BMMSCs - 100 million)",
                "Pilot Phase: Group 3 (BMMSCs - 20 million)",
                "Pilot Phase: Group 4 (BMMSCs -100 million)"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Placebo",
            "InterventionDescription": "a single administration of placebo delivered via peripheral intravenous infusion.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group E (Placebo)"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of any treatment-emergent serious adverse events (TE-SAEs)",
            "PrimaryOutcomeDescription": "Incidence (at one-month post infusion) of any treatment-emergent serious adverse events (TE-SAEs), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities, determined per the Investigator's judgment.",
            "PrimaryOutcomeTimeFrame": "one month post infusion"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change of inflammatory markers",
            "SecondaryOutcomeDescription": "Change between baseline and 6 months for the following panel of inflammatory markers: C-reactive protein, Interleukin-6, D-dimer, fibrinogen, Complete blood count with differential, and TNFα.",
            "SecondaryOutcomeTimeFrame": "Baseline and at 6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Effect on Frailty Phenotype Score",
            "SecondaryOutcomeDescription": "to measure if intervention with UCMSCs versus BMMSCs has a beneficial effect on Cardiovascular Health Study (CHS) Frailty Phenotype Score.",
            "SecondaryOutcomeTimeFrame": "baseline, 3 and 6 months' follow-up visits"
          },
          {
            "SecondaryOutcomeMeasure": "Effect on Physical Performance through Quality of Life questionnaires",
            "SecondaryOutcomeDescription": "to measure if intervention with UCMSCs versus BMMSCs has a beneficial effect on physical performance by comparing quality of life questionnaires.",
            "SecondaryOutcomeTimeFrame": "baseline, 3 and 6 months' follow-up visits"
          },
          {
            "SecondaryOutcomeMeasure": "Change of Pro-inflammatory cytokines in laboratory analysis",
            "SecondaryOutcomeDescription": "to measure if intervention with UCMSCs versus BMMSCs reduces pro-inflammatory cytokines, and the relationship between these cytokines.\n\nAssess change for the following panel of inflammatory markers: CRP, IL-6, D-dimer, fibrinogen, CBC with differential, and TNFα.",
            "SecondaryOutcomeTimeFrame": "baseline, 3 and 6 months' follow-up visits"
          },
          {
            "SecondaryOutcomeMeasure": "Determine if there is an improvement in symptoms between subjects receiving umbilical cord cells versus bone marrow cells",
            "SecondaryOutcomeDescription": "to measure if intervention with UCMSCs versus BMMSCs improves composite clinical outcomes / symptoms in congestive heart failure subjects.",
            "SecondaryOutcomeTimeFrame": "baseline, 3 and 6 months' follow-up visits"
          },
          {
            "SecondaryOutcomeMeasure": "Number of study participants experiencing safety events (difference between dose and placebo subjects)",
            "SecondaryOutcomeDescription": "To measure the safety of three doses of UCMSCs versus BMMSCs compared to placebo in congestive heart failure.",
            "SecondaryOutcomeTimeFrame": "baseline, 3 and 6 months' follow-up visits"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nProvide written informed consent\nSubjects age > 21 and < 95 years at the time of signing the Informed Consent Form.\nEach subject must have endothelial dysfunction.\n\nEndothelial dysfunction Criteria:\n\nImpaired flow-mediated vasodilation (FMD <7%)\n\n• At the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following:\n\nWaist circumference - US defined: ≥ 102 cm (males) or ≥ 88 cm (females)\nElevated triglycerides - ≥ 150 mg/dL (1.7 mM)\nReduced HDL-C - Males: <40 mg/dL (1.0 mM) Females: <50 mg/dL (1.3 mM)\nElevated blood pressure - Systolic ≥ 130 mm Hg and/or Diastolic ≥ 85 mm Hg\nElevated fasting glucose - ≥ 100 mg/dL\n\nExclusion Criteria:\n\nBe a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.\nInability to perform any of the assessments required for endpoint analysis.\nActive listing (or expected future listing) for transplant of any organ.\nClinically important abnormal screening laboratory values, as determined by the P.I.\nSerious comorbid illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.\nHave known allergies to penicillin or streptomycin.\nHypersensitivity to dimethyl sulfoxide (DMSO).\nBe a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior enrollment) bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.\nHave a clinical history of malignancy within 3 years (i.e., subjects with prior malignancy must be disease free for 3 years), except curatively- treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma, if recurrence occurs.\nHave a non-pulmonary condition that limits lifespan to < 1 year.\nHistory of drug abuse (illegal \"street\" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months.\nBe serum positive for HIV, hepatitis BsAg or Viremic hepatitis C, and/or Syphilis - VDRL (Confirmation with FTA-ABS if needed (Syphilis)).\nBe currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.\nPatients with EF<45% (heart failure patients).\nGFR < or equal to 35 (chronic kidney disease stage 3 or higher).\nLiver disease (elevated LFTs greater than 3x normal limit).\nAdvanced pulmonary disease (requiring home oxygen and/or less than 1 expected life span).\nProliferative diabetic retinopathy\nHemoglobin A1C greater than 7.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "21 Years",
      "MaximumAge": "95 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Joshua M Hare, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "305-243-5579",
            "CentralContactEMail": "jhare@med.miami.edu"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Joshua M Hare, MD",
            "OverallOfficialAffiliation": "ISCI / University of Miami Miller School of Medicine",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "ISCI / University of Miami Miller School of Medicine",
            "LocationStatus": "Recruiting",
            "LocationCity": "Miami",
            "LocationState": "Florida",
            "LocationZip": "33136",
            "LocationCountry": "United States",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Joshua M Hare, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "305-243-5579",
                  "LocationContactEMail": "jhare@med.miami.edu"
                },
                {
                  "LocationContactName": "Coordinators",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "305-243-7444",
                  "LocationContactEMail": "ISCIStudyInfo@miami.edu"
                },
                {
                  "LocationContactName": "Joshua M Hare, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Interdisciplinary Stem Cell Institute at the University of Miami Miller School website",
            "SeeAlsoLinkURL": "http://isci.med.miami.edu"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000024821",
            "ConditionMeshTerm": "Metabolic Syndrome"
          },
          {
            "ConditionMeshId": "D000013577",
            "ConditionMeshTerm": "Syndrome"
          },
          {
            "ConditionMeshId": "D000007249",
            "ConditionMeshTerm": "Inflammation"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000004194",
            "ConditionAncestorTerm": "Disease"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000007333",
            "ConditionAncestorTerm": "Insulin Resistance"
          },
          {
            "ConditionAncestorId": "D000006946",
            "ConditionAncestorTerm": "Hyperinsulinism"
          },
          {
            "ConditionAncestorId": "D000044882",
            "ConditionAncestorTerm": "Glucose Metabolism Disorders"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M15507",
            "ConditionBrowseLeafName": "Syndrome",
            "ConditionBrowseLeafAsFound": "Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9445",
            "ConditionBrowseLeafName": "Inflammation",
            "ConditionBrowseLeafAsFound": "Inflammation",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M22158",
            "ConditionBrowseLeafName": "Metabolic Syndrome",
            "ConditionBrowseLeafAsFound": "Metabolic Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9522",
            "ConditionBrowseLeafName": "Insulin Resistance",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9149",
            "ConditionBrowseLeafName": "Hyperinsulinism",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M24556",
            "ConditionBrowseLeafName": "Glucose Metabolism Disorders",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          }
        ]
      }
    }
  }
}